AdvaMed urges user fee renewal as negotiated; Quest Diagnostics boosts revenue;

@FierceMedDev: Abbott Breakup Plans Are on Target as Profit Tops Estimates | Bloomberg. Article | Follow @FierceMedDev

> AdvaMed is urging Congress to ensure "swift passage" of the medical device user fee authorization renewal as negotiated. Release

> Abbott Laboratories ($ABT) says plans to split off into a two companies--one focused on new drugs, the other, on medical devices, generic medicines and nutritional drinks--are on track for completion by the end of 2012. Story

> Quest Diagnostics boosted revenue 6.3% to $1.9 billion for its fiscal 2012 first quarter, driven by a 6.4% jump in clinical testing revenue, a number that spiked a bit due to acquisitions. Release

> A Senate committee later this month will consider a newly filed bill designed to ensure pediatric studies are completed for devices and drugs; make sure studies are planned earlier in the development process; and make permanent the pediatric medical device incentive and the pediatric device consortia initiative. Release

> Italian researchers say that a new "fast and inexpensive" imaging technique known as digital chest tomosynthesis is showing promise as a way to screen for lung cancer. Release

Pharma News

@FiercePharma: Pfizer's still working with Nestle and Danone in nutrition-unit sale, Bloomberg says, though Danone thinks it won't win. Article | Follow @FiercePharma

> Another day, another deal for Valeant's Pearson. Story

> J&J plant fixes behind schedule, hampering brands' return. Report

> Humira sales leap helps power Abbott earnings. Item

> Mylan pledges 500 new jobs in Irish expansion. Article

> WSJ: Pfizer poised to sell nutrition biz to Nestlé for $9B-plus. News

Biotech News

@FierceBiotech: Fierce's Top 10 Late-Stage Cancer Drugs -- 2012. Report | Follow @FierceBiotech

@JohnCFierce: GSK doubles down on drug discovery collaboration with FivePrime, a Fierce 15 company in 2004. News | Follow @JohnCFierce

@RyanMFierce: Google VC fuels Series A round for pharma software startup Wingu, aims to capitalize on open R&D trend. Story | Follow @RyanMFierce

> Abbott touts positive Parkinson's PhIII as pharma split looms. More

> Crucell and Royal DSM pull the plug on biosimilar JV. News

> J&J and Bristol-Myers ally on another potential hep C blockbuster. Article

> Roche says it won't extend Illumina offer past Friday deadline. Item

Drug Delivery News

> Meet the new editor of FierceDrugDelivery. Item

> Novo: Delivery devices could make biosimilars unsafe. More

> Dutch firm gets Fox Foundation funding for PD tech. Story

> BDSI gets patent for anti-opioid film. News

> pSivida stock rallies after Durasert partnerships. Article

Biomarkers News

> Saliva test could aid dentists in oral cancer diagnosis. Story

> RNA markers for blast-induced traumatic brain injury. Item

> Postmenopausal osteoporosis fingerprinted by miRNAs. More

> Chemo-resistance proteins mark defiant breast tumors. Article

And Finally... Competitive bidding for power wheelchairs, diabetic supplies and other personal medical equipment helped save Medicare $200 million last year, the agency says. Story

Suggested Articles

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.

More than 20 states either don’t release or have incomplete data on the rapid antigen tests now considered key to containing the coronavirus.